Pfizer (PFE)
23.93
-0.22 (-0.91%)
NYSE · Last Trade: Sep 19th, 2:32 PM EDT
Detailed Quote
Previous Close | 24.15 |
---|---|
Open | 24.25 |
Bid | 23.92 |
Ask | 23.93 |
Day's Range | 23.82 - 24.25 |
52 Week Range | 20.92 - 30.43 |
Volume | 42,283,249 |
Market Cap | 134.17B |
PE Ratio (TTM) | 12.73 |
EPS (TTM) | 1.9 |
Dividend & Yield | 1.720 (7.19%) |
1 Month Average Volume | 41,103,436 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic forecasts are largely fueled by the unprecedented success of its incretin-based medications, Mounjaro and Zepbound, which have become dominant
Via MarketMinute · September 19, 2025
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like peptide-1) market. This fierce competition, fueled by blockbuster drugs for diabetes and weight loss, is not merely a corporate rivalry; it's a pivotal
Via MarketMinute · September 19, 2025
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery for biotechnology companies. This strategic move aims to level the playing field, granting smaller biotechs access to sophisticated AI models trained on decades
Via MarketMinute · September 19, 2025
Looking for the most active stocks in the S&P500 index on Friday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · September 19, 2025
Everything is going great for the stock market right now. But a plot twist could be on the way.
Via The Motley Fool · September 19, 2025
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.
Via The Motley Fool · September 19, 2025
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.
Via Benzinga · September 18, 2025
Washington D.C. - The U.S. Federal Reserve finds itself at a critical juncture, facing an economic environment that is increasingly raising the specter of "stagflation" – a challenging combination of elevated inflation and a softening labor market. In a significant policy shift, the Fed recently cut its benchmark interest
Via MarketMinute · September 18, 2025
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.
Via Investor's Business Daily · September 18, 2025
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Via StockStory · September 18, 2025
The U.S. Federal Reserve’s recent decision to cut interest rates has sent a tremor of concern through financial markets, sparking fears of a potential return to stagflation—an economic phenomenon characterized by the unsettling combination of stagnant growth, high unemployment, and persistent inflation. This unprecedented monetary easing comes
Via MarketMinute · September 17, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant
By Arvinas Inc. · Via GlobeNewswire · September 17, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · September 17, 2025
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.
Via The Motley Fool · September 17, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · September 17, 2025
Nvidia, Pfizer, New Fortress Energy, Tesla, Alphabet: What Sparked Heavy After-Hours Trading In These 5 Stocks?stocktwits.com
Via Stocktwits · September 17, 2025
In a development that has sent ripples of concern through financial markets, the U.S. Treasury yield curve underwent a significant un-inversion in April 2025, following its longest inversion in history, spanning from 2022 through 2024. This shift, characterized by short-term interest rates falling below long-term rates once again, initially
Via MarketMinute · September 16, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · September 16, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®.
Via StockStory · September 16, 2025
In an otherwise hot stock market, healthcare stocks are underperforming.
Via The Motley Fool · September 16, 2025
Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.
Via Benzinga · September 16, 2025
Pfizer has an attractive 7.2% dividend yield, but this healthcare giant might be a riskier dividend stock than you want to own.
Via The Motley Fool · September 16, 2025
A good stock is an even better buy when it's on sale, even if your primary goal is immediate and reliable income.
Via The Motley Fool · September 16, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Via StockStory · September 16, 2025